andrew will provide an overview of select financial items.
today 's discussion and the supporting materials will include references to adjusted eps , adjusted ebitda , adjusted cash from operations , free cash flow and organic revenue growth , all of which are non-gaap financial measures.
a reconciliation and definition of these terms as well as other non-gaap financial terms to which we may refer during today 's conference call are provided on our website.
actual results may vary based upon these risks and uncertainties.
our second quarter results , revenue up 8 % , ebitda up 2 % and earnings per share up 5 % year - over - year were slightly ahead of our guidance.
these results were fundamentally driven by volume , reflecting robust demand for fmc products around the world.
our research laboratories and greenhouses also have continued to operate throughout the pandemic.
information presented represents our best judgment based on today 's understanding.
all our manufacturing facilities and distribution warehouses remain operational and properly staffed.
innovation continues to be a catalyst for growth.
i 'd like to take a moment to provide a covid - 19 update on our business.
we are resuming in - office operations work permitted by local authorities.
new products introduced in the last 12 months contributed $ 30 million in sales growth in the quarter and our plant health products , including biologicals , posted q2 sales growth in the high teens.
we will go into this in more details later.
we continue to expect a very strong second half of 2021 , driven by robust volume growth.
we have lowered our full year earnings guidance due to the continued acceleration of raw material , packaging and logistics costs.
